A CT scan exposes one to low doses of ionizing radiation.
The result is radiation induced genomic damage and instability, or “RIGDI” — a key precursor to carcinogenesis. RIGDI has been found to be a key precursor to carcinogenesis. Damaged or unstable cells left unrepaired or repaired incorrectly can lead to mutations into abnormal cells, which may become cancerous or lead to other serious medical conditions.
Even the smallest amount of radiation exposure can initiate genomic instability and/or genomic damage.
Research has shown that cumulative radiation exposure of 100 Millisieverts (mSv) (from as few as 2 CT scans*) delivers a 1% increase in the lifetime attributable risk (LAR) of cancer and 0.5% risk of fatal cancers.
A much lower dose of AmiGuard than FDA-approved Amifostine — taken either in advance of or before and after a CT Scan — acts as a genomic stabilizing agent to prevent RIGDI.
The protocol produces a shell-like structure to protect DNA from radiation and, in situations of radiation exposure, invokes an antioxidant response that facilitates fidelity of cell repair.
F3 research validates the safety and efficacy of AmiGuard CT for the protection and repair of human cells exposed to low dose ionizing radiation.
Our research concludes that substantial protection can be achieved at 80-90% of the current FDA approved dose of Amifostine.
*Research indicates that radiation exposure ranges may be 22 to 33 mSv for CT scans of the chest, pelvis, and abdomen